AveragePenny
3年前
$YECO EV Biologics Updates on Funding and Sales
https://www.accesswire.com/789178/ev-biologics-updates-on-funding-and-sales
TAMPA, FL / ACCESSWIRE / October 2, 2023 / EV Biologics Corp, (OTC Pink:YECO), today announced that it has closed a $500,000 interest-free loan from a related party.
This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.
The Company has already begun sales of some of its regenerative products through its agents in Asia for pre-clinical use and testing and expects to start sales in South America by November this year. The Company filed an application for a trademark under the product name: EcoCura with the U.S. Trademark Office on September 22, 2023.
As reported in the August 7, 2023 press release, the Company is moving with audits and the filing with FINRA for the name and symbol change. Furthermore, our Director of Corporate Finance, William Bossung is heading up our efforts to re-apply to up-list to Nasdaq.
CEO, Daniel Mckinney, said "Our audacious goal is to revolutionize modern medicine by harvesting the healing power naturally produced by living cells to develop versatile therapeutics and enable safe and effective treatment of a wide range of clinical conditions for better health & longevity.
To minimize capital requirements, Excyte is developing essential product and process technologies in parallel with its primary therapeutic development pathway through collaboration with best-in-class commercial partners. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.
AveragePenny
3年前
$YECO EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
https://www.accesswire.com/774507/EV-Biologics-Completes-Production-of-Cutting-Edge-MSC-Exosome-Based-Therapeutic
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
CEO, Daniel Mckinney said: "As stated, creating novel regenerative medicines to promote health and longevity is our top priority - essentially, our goal is to produce the ‘Fountain of Youth'. Most biotech companies only engage in endless rounds of research and development. We now have a product that we intend to start using in clinical trials in Asia, the Middle East and in South America. There is now hope for old age, frailty, and a host of other illnesses with this revolutionary product. "
Bardo
3年前
New PR coming out regularly now …. Very nice
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
CEO, Daniel Mckinney said: "As stated, creating novel regenerative medicines to promote health and longevity is our top priority - essentially, our goal is to produce the ‘Fountain of Youth'. Most biotech companies only engage in endless rounds of research and development. We now have a product that we intend to start using in clinical trials in Asia, the Middle East and in South America. There is now hope for old age, frailty, and a host of other illnesses with this revolutionary product. "
AveragePenny
4年前
$YECO EV Biologics Updates on Excyte Subsidiary Funding
https://www.accesswire.com/733763/ev-biologics-updates-on-excyte-subsidiary-funding
TAMPA, FL / ACCESSWIRE / January 3, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has now closed $1,000,000 of its $2.5 million initial capitalization goal.
One hundred thousand shares (100,000) have been issued at $10 per share, out of a total issuance of ten million shares to EV Biologics. Excyte, a wholly owned subsidiary, was launched in August 2022, with $100 Million valuation. The Company aims to close the balance of the capital raise before the end of Q1, 2023.
This funding will provide for further optimization of our primary stem cell bank isolation and expansion along with scale-down biomanufacturing process development. Some of these funds will also be allocated to analysis of the biomolecular composition and the biological activity of composite stem cell secretome products and their constituent vesicular and non-vesicular nanoparticle fractions to advance EV Biologics' ongoing secretome product development.
CEO, Daniel Mckinney, said "By illuminating the complex mechanisms and principal bioactive components of the stem cell secretome, we can accelerate our product and process development toward standardized biomanufacturing of our regenerative therapeutics for better health and longevity. Our audacious goal is to revolutionize modern medicine by unraveling the complex mechanisms of stem cell therapy and apply this understanding to recreate defined regenerative therapeutics."
To execute its biotechnology innovations and minimize capital requirements, Excyte is developing essential product and process technologies in parallel with its primary therapeutic development pathway through collaboration with best-in-class commercial partners. Intellectual property, patents, proprietary process, and product development will be held by Excyte in support of EV Biologics.
Bardo
4年前
EV Biologics Signs MSA with LONZA Cell & Gene Therapy
Press Release | 05/17/2022
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.
The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in cell and gene therapy.
EV Biologics has been developing nanotherapeutic-producer cells and optimizing a process for isolation of primary cells from tissue and expansion of cell banks using defined cell culture conditions. The Company is very pleased to announce that advancing its relationship with Lonza will accelerate development and implementation of rigorous upstream and downstream biomanufacturing processes that will facilitate production of more consistent nanotherapeutic candidates.
CEO, Daniel Mckinney, said "We are very excited to enter the next phase of our business relationship with Lonza, the world's premier biomanufacturing firm for further process development. This represents a significant step toward our goal of developing high-quality nanotherapeutics for a broad range of clinical conditions. Furthermore, we are maximizing our resources and multiplying our efficiency by leveraging the assets of best-in-class partners like Lonza, rather than investing tens of millions in our own physical infrastructure for laboratory and manufacturing facilities."
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. They focus on enabling treatments that prevent illness and support healthier lifestyles. They optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
They provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Their scale and resources mean they can provide a one-stop solution for our customers to help people get well, feel well, and stay well. In 2021, we supported more than 780 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced around 250 billion capsules.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), they comprise high-performing teams
and individual talent that make a meaningful difference to their own businesses, as well as to the communities in which they operate. Their business benefits from global supply chains, but have worked to maintain the agility to address marketplace needs on a local level.
A firm commitment to responsible business and sustainability underpins everything they do. Minimizing their impact on the environment, conserving energy and natural resources, and helping to improve life quality are all central to our culture. Lonza's Vision Zero initiative is a prime example, as they strive to achieve zero workplace accidents and injuries, zero environmental incidents, zero product transportation incidents and zero manufacturing process incidents. They work to attract and retain the best talent, to make a meaningful difference to their own business, as well as to the communities in which they operate.
Lonza generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. The Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI). They also maintain a secondary listing on the SGX Singapore Exchange. For more information about Lonza: www.lonza.com
Bardo
5年前
NASHVILLE, TN / ACCESSWIRE / October 28, 2021 / EV Biologics Corp, OTC Pink:YECO, today updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders.This review discusses some of the cellular and molecular pathology of COVID-19 and the relevant therapeutic mechanisms of small extracellular vesicles (EVs), such as exosomes, in Acute Lung Injury (ALI). The original manuscript was initially prepared by Dr. Sanders in March 2020, near the beginning of the pandemic, to illustrate the therapeutic potential of mesenchymal stem cell (MSC) exosomes in this type of disease. Since that time, a number of clinical trials investigating MSC exosomes as a therapy for COVID-19 have been initiated.Please download the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225928/.CMO Dr. Jason Sanders said: "This publication presents only a very small fraction of the potential of EV-based therapeutics produced by MSCs and other stem cells. Through convergence of multiple revolutionary technologies, we are advancing our objectives to capture the remarkable therapeutic potential of MSCs, to optimize it for a breadth of focused clinical applications, and to standardize the products and processes for preparation of next-generation therapeutics."EV Biologics is developing optimized clonal stem cell lines for biomanufacturing of naïve and engineered EV-based therapeutics that will be developed into biological drugs seeking FDA approval for several different clinical indications: acute lung injury (eg. COVID-19, influenza, acute respiratory distress syndrome), autoimmune (lupus, multiple sclerosis, rheumatoid arthritis, etc) and systemic inflammatory syndromes, osteoarthritis and other degenerative musculoskeletal disease, neurodegenerative conditions, metabolic diseases, and other age-related conditions.CEO Daniel Mckinney, said "EV Biologics has adopted a very advanced technological approach to biopharmaceutical development that will rapidly develop and efficiently manufacture EV-based therapeutics within a rigorous cGMP framework to prepare investigational new drugs, far superior to anything currently on the market, for submission to FDA. Our audacious goal is to conquer incurable diseases and revolutionize modern medicine to deliver better health for patients worldwide."About the CompanyEV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in thesebioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.Forward-Looking StatementsThis news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.Contact:Dennis BurnsInvestor RelationsTel(567)237-4132dburns@nvestrain.comFor more information on EV Biologics please visit: www.evbiologics.comSOURCE: EV Biologics Corp,View source version on accesswire.com: https://www.accesswire.com/670115/EV-Biologics-Chief-Medical-Officer-Publication-on-COVID-19-Exosomes
AskMuncher
5年前
$YECO EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research
Press Release | 04/08/2021
NASHVILLE, TN / ACCESSWIRE / April 8, 2021 /EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a director's loan agreement to secure funding of up to $5 million to start generation of a novel exosome-producer cell line and production of therapeutic exosomes for preclinical research.
The Company has finalized its preparation and is ready to begin generation of a novel exosome-producer master cell bank to enable manufacturing of therapeutic exosomes with improved intrinsic bioactivity at a commercially relevant scale. Our internal research indicates that this producer cell line and its derivatives will produce exosomes with native bioactivity superior to those manufactured using common producer cells, such as mesenchymal stem cells isolated from bone marrow, adipose tissue or umbilical cord, or exosomes found naturally in amniotic fluid.
This internal funding will finance immediate generation of this master cell bank, which will serve as a versatile platform for production of exosomes with a broad scope of potential clinical applications. These funds will also enable immediate production of research-grade exosomes from induced pluripotential stem cells (iPSCs) and their derivatives for evaluation of native exosome bioactivity and further bioengineering. This research will inform and expedite our ongoing effort to engineer exosomes optimized for specific clinical applications.
CEO Daniel Mckinney, said "we have set an aggressive timeline to produce our own optimized cell line and exosomes, and with this funding we will achieve it. Our ultimate audacious goal is to conquer incurable diseases and to revolutionize modern medicine."
The director's loan will be repaid in cash after the intended security token sale later this summer. No shares will be issued pursuant to any future funding.
EV Biologics is building a world-class team of exosome biotechnology experts specializing in molecular biology, biochemical engineering, biomanufacturing, cellular biochemistry, bioinformatics and computational biology.
Please visit our website: www.evbiologics.com/about
EV Biologics was previously a NASDAQ-listed company and intends to up-list to a mainboard exchange again before the end of 2021.
Exosomes
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. - Cells, 2020
The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer. Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. - Science, 2020
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.
Contact:
Dennis Burns
Investor Relations
Tel(567)237-4132
dburns@nvestrain.com
For more information on EV Biologics please visit:
www.evbiologics.com
SOURCE: EV Biologics Corporation
View source version on accesswire.com:
https://www.accesswire.com/639457/EV-Biologics-Confirms-Funding-to-Commence-Cell-Line-Generation-Advance-Exosome-Research
AskMuncher
5年前
$YECO EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research
Press Release | 04/08/2021
NASHVILLE, TN / ACCESSWIRE / April 8, 2021 /EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a director's loan agreement to secure funding of up to $5 million to start generation of a novel exosome-producer cell line and production of therapeutic exosomes for preclinical research.
The Company has finalized its preparation and is ready to begin generation of a novel exosome-producer master cell bank to enable manufacturing of therapeutic exosomes with improved intrinsic bioactivity at a commercially relevant scale. Our internal research indicates that this producer cell line and its derivatives will produce exosomes with native bioactivity superior to those manufactured using common producer cells, such as mesenchymal stem cells isolated from bone marrow, adipose tissue or umbilical cord, or exosomes found naturally in amniotic fluid.
This internal funding will finance immediate generation of this master cell bank, which will serve as a versatile platform for production of exosomes with a broad scope of potential clinical applications. These funds will also enable immediate production of research-grade exosomes from induced pluripotential stem cells (iPSCs) and their derivatives for evaluation of native exosome bioactivity and further bioengineering. This research will inform and expedite our ongoing effort to engineer exosomes optimized for specific clinical applications.
CEO Daniel Mckinney, said "we have set an aggressive timeline to produce our own optimized cell line and exosomes, and with this funding we will achieve it. Our ultimate audacious goal is to conquer incurable diseases and to revolutionize modern medicine."
The director's loan will be repaid in cash after the intended security token sale later this summer. No shares will be issued pursuant to any future funding.
EV Biologics is building a world-class team of exosome biotechnology experts specializing in molecular biology, biochemical engineering, biomanufacturing, cellular biochemistry, bioinformatics and computational biology.
Please visit our website: www.evbiologics.com/about
EV Biologics was previously a NASDAQ-listed company and intends to up-list to a mainboard exchange again before the end of 2021.
Exosomes
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. - Cells, 2020
The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer. Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. - Science, 2020
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.
Contact:
Dennis Burns
Investor Relations
Tel(567)237-4132
dburns@nvestrain.com
For more information on EV Biologics please visit:
www.evbiologics.com
SOURCE: EV Biologics Corporation
View source version on accesswire.com:
https://www.accesswire.com/639457/EV-Biologics-Confirms-Funding-to-Commence-Cell-Line-Generation-Advance-Exosome-Research
AskMuncher
6年前
$YECO EV Biologics Signs Funding Agreement for Biotech Security Token Offering
Press Release | 12/02/2020
CHEYENNE, WY / ACCESSWIRE / December 2, 2020 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a funding agreement with an investment bank to sponsor the raise of $25-$50 million for research and development via a Security Token Offering "STO" - a worlds' first in Biotech.
The Company will start this innovative blockchain funding program starting January 1, 2021 that will fund the research and development for Acute Lung Injury "ALI". The STO is a system of securitizing a real-world, hard assets and offering it to the public in a SEC regulated process utilizing blockchain technology. This will give investors another way to participate in the direct ownership of the Company's assets, intellectual property "IP", information technology "IT" and patents and greatly increase YECO's value through its majority stake in the ALI backed security token. The Company's Security Token will be registered with the SEC and trade on a digital exchange.
The Company will tokenize and issue 100 million ALI tokens and sell up to $50 million of Tokens at $5.00 per token.
YECO is not issuing any shares, thus not diluting the existing shareholders. This new financing model will add tremendous equity and value to the Company as the majority of AIL Tokens will remain on the Company balance sheet.
CEO Daniel Mckinney, said "we are now the first biotech company in the world to issue a STO for funding. We are also the first biotech listed company to blend a STO with our public listing. We are most enthusiastic about its potential and dynamics."
EV Biologics will focus exclusively on our R&D program for ALI and the resulting biopharmaceuticals, along with preparations for submissions of the corresponding Investigational New Drug applications "INDs" to the FDA.
YECO was previously a Nasdaq listed company and intends to up-list to OTCQB, then to a mainboard exchange again.
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.
Contact:
Dennis Burns
Investor Relations
Tel(567)237-4132
dburns@nvestrain.com
For more information on EV Biologics please visit:
www.evbiologics.com
SOURCE: EV Biologics Corporation
View source version on accesswire.com:
https://www.accesswire.com/619143/EV-Biologics-Signs-Funding-Agreement-for-Biotech-Security-Token-Offering
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
メールアドレスで登録
